Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of Serono Symposia International Foundation. All presentations solely represent the independent views of the presenters/authors.
The following faculty indicated no significant commercial relationships and/or discussions of investigational or non- EMEA/FDA approved (off-label) uses of drugs:
Georg Brabant
Alain Golay
Luigi Saccà
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non- EMEA/FDA approved (off-label) uses of drugs:
Pierre Chatelain: Declared receipt of honoraria or consultation fees from Merck-Serono as Co-investigator in sponsored clinical trial
Jens Otto Lunde Jørgensen: Declared receipt of grants and contracts from Pfizer, Ipsen and honoraria or consultation fees from Pfizer, Ipsen, Novartis, NovoNordisk
Mats Rudling: Declared to be cofounder of Sahltech AB in Gothenburg, Sweden
